Invesaro

Stocks Industrials FZMD

OTC · Industrials

Fuse Medical, Inc. (FZMD)

Fuse Medical, Inc. brought in $18.4M of revenue over the twelve months to June 30, 2023, down 5.8% from a year earlier. Net income was $4M, a net margin of 21.6%. At June 30, 2023 it held $253.4K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2023.

Watch FZMD in 60 seconds
Price
$0.03
+40.00% on the day · September 25, 2026
52-week range $0.02 to $0.08
Market cap
$2.1M
Revenue (last 12 months)
$18.4M
-5.8% year on year
Net margin
21.6%
P/E
0.7
on FY2022 diluted EPS

What Fuse Medical, Inc. does

Fuse Medical, Inc. is registered with the SEC under industry code SIC 5047 (Wholesale-Medical, Dental & Hospital Equipment & Supplies). Its shares trade on OTC under the ticker FZMD.

Revenue and profit by year

Revenue
FY15: $1.7M $1.7M FY15FY16: $25.7M $25.7M FY16FY17: $26.4M $26.4M FY17FY18: $26.3M $26.3M FY18FY19: $22.9M $22.9M FY19FY20: $21.4M $21.4M FY20FY21: $20.4M $20.4M FY21FY22: $18.6M $18.6M FY22
Net income
FY15: -$801.5K -$801.5K FY15FY16: $3M $3M FY16FY17: $699.7K $699.7K FY17FY18: $4M $4M FY18FY19: -$3.3M -$3.3M FY19FY20: -$1.4M -$1.4M FY20FY21: -$1.6M -$1.6M FY21FY22: $3.1M $3.1M FY22

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2022$18.6M-$815.1K$3.1M$0.04n/a
2021$20.4M-$2.2M-$1.6M-$0.02n/a
2020$21.4M-$1M-$1.4M-$0.02$215.9K
2019$22.9M-$4.3M-$3.3M-$0.05-$20.1K
2018$26.3M-$2M$4M$0.05$2.4M
2017$26.4M$858.9K$699.7K$0.03$1.6M

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Fuse Medical, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 27, 2023
  2. September 27, 2023
  3. August 15, 2023
  4. August 14, 2023
    Quarterly report 10-Q · period to June 30, 2023Revenue rose 7% to $5M versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  5. June 26, 2023
  6. May 15, 2023
    Quarterly report 10-Q · period to March 31, 2023Revenue fell 13% to $4M versus the same quarter last year; diluted EPS $0.00 versus -$0.01.
  7. May 10, 2023
  8. May 10, 2023
  9. May 10, 2023
  10. April 18, 2023

Recent insider filings (Forms 3, 4 and 144): 10, the latest on December 16, 2022. Insider transactions on SEC

All filings on SEC EDGAR

Questions about FZMD

What does Fuse Medical, Inc. do?

Fuse Medical, Inc. is registered with the SEC under industry code SIC 5047 (Wholesale-Medical, Dental & Hospital Equipment & Supplies). Its shares trade on OTC under the ticker FZMD.

Is Fuse Medical, Inc. profitable?

Yes. Over the twelve months to June 30, 2023 it reported net income of $4M on revenue of $18.4M, a net margin of 21.6%.

How much revenue does Fuse Medical, Inc. make?

Over the twelve months to June 30, 2023 Fuse Medical, Inc. reported revenue of $18.4M. That is 5.8% less than a year earlier.

When did Fuse Medical, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2023. It covers the period to June 30, 2023. Its newest filing of any kind is the deregistration from September 27, 2023.

Similar companies

Compare FZMD with

Compare FZMD with any company

Follow FZMD

Get an email when Fuse Medical, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow FZMD: get an email when it files

Where the numbers come from

Financial figures are the values Fuse Medical, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.